23 / 27
Page 79
allied
academies
J Pharmacol Ther Res 2017 Volume 1 Issue 2
November 02-03, 2017 Chicago, USA
4
th
International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
O
steosarcoma (OS) is the most common malignant
tumor that develops in bone. Its mortality is very high.
Therefore, study of mechanisms of pathogenesis of the OS is
urgently required. Previous studies ofmicroarray showed that
the expression levels of matrix metallopeptidase 9 (MMP-9)
altered significantly in OS. In addition, overexpression of
MMP-9 is recognized as an indicator in cancer. However, the
exact roles of MMP-9 in OS are not fully investigated. Thus,
we firstly studied the roles of MMP-9 in OS and revealed
that silence of MMP-9 inhibited OS cell proliferation as
determined by MTT assay and colony formation assay.
Secondly, we conducted TUNEL assay and found loss of
functions of MMP-9 induced OS cell apoptosis. Next, we
used lentivector packaging method to overexpress MMP-9
and found that overexpression of MMP-9 promoted OS cell
migration. Fourthly, the results of luciferase assay showed
that MMP-9 was targeted by hsa-miR-494, which inhibited
OS. Fifthly, we revealed that the levels of hsa-miR-494 were
upregulated by the drug silybin which inhibited OS cell
proliferation. Finally, we revealed that silybin inhibited OS
cell viability by altering the protein levels of β-catenin and
Runt-related transcription factor 2 (RUNX2) as determined
by western blot and immunocytochemistry (ICC).
e:
sunmishu@126.comMMP-9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma
Tianhao Sun, Frankie Leung
and
William W Lu
University of Hong Kong, China